-
Bilex Pharma Launches Project SHIELD to Address Major Respiratory Viral Threats
Bilex Pharma is pleased to announce the launch of Project SHIELD, a comprehensive initiative focused on developing next-generation vaccines against major respiratory viral pathogens. This strategic program integrates the company’s most advanced clinical candidates with innovative research efforts aimed at transforming the prevention of respiratory viral diseases. A Unified Approach to Respiratory Viral Threats Project…
About
At Bilex Pharma, we envision a world where innovative vaccines provide effective protection against both established and emerging infectious diseases, enabling healthier communities and more resilient global health systems.
We focus our expertise on significant health challenges where current solutions are inadequate or nonexistent. By targeting diseases with substantial global burden and limited preventive options, we strive to make meaningful contributions to public health where they’re needed most.
Archive
Categories
Recent Posts
- Bilex Pharma Completes Patient Enrollment for Landmark Phase 3 Trial of RSV Vaccine Candidate BLX-RSV01 in Older Adults
- Bilex Pharma’s Next-Generation COVID-19 Vaccine BLX-COVID19 Shows Superior Immune Response with Reduced Dosing in Phase 2 Trial
- Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
- Bilex Pharma’s Universal Influenza Vaccine Candidate Shows Promising Cross-Strain Protection in Phase 2b Interim Analysis
- Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial